Skip to Content
Merck
  • Discovery of butyrylcholinesterase inhibitors among derivatives of azaphenothiazines.

Discovery of butyrylcholinesterase inhibitors among derivatives of azaphenothiazines.

Journal of enzyme inhibition and medicinal chemistry (2014-03-29)
Krzysztof Lodarski, Jakub Jończyk, Natalia Guzior, Marek Bajda, Joanna Gładysz, Joanna Walczyk, Małgorzata Jeleń, Beata Morak-Młodawska, Krystian Pluta, Barbara Malawska
ABSTRACT

The study presents the discovery of novel butyrylcholinesterase (BuChE) inhibitors among derivatives of azaphenothiazines by application of in silico and in vitro screening methods. From an in-house library of compounds, 143 heterocyclic molecules derived from the azaphenothiazine scaffold were chosen for virtual screening. Based on results of the docking procedure, 15 compounds were identified as exhibiting the best fit for the two screening complexes (ligand - AChE and ligand - BuChE). Five compounds displayed moderate AChE and good BuChE inhibitory activity at screening concentrations of 10 µM. The IC50 values for active BuChE inhibitors were in the 11.8-122.2 nM range. Three of the most active inhibitors are tetra- or pentacyclic derivatives of azaphenothiazines with the same N-methyl-2-piperidinethyl substituent.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Chloroform-d, 99.8 atom % D, contains 0.03 % (v/v) TMS
Sigma-Aldrich
Chloroform-d, 99.8 atom % D
Sigma-Aldrich
5,5′-Dithiobis(2-nitrobenzoic acid), ReagentPlus®, 99%
Sigma-Aldrich
5,5′-Dithiobis(2-nitrobenzoic acid), ≥98%, BioReagent, suitable for determination of sulfhydryl groups